BridgeBio Pharma Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of BridgeBio Pharma Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 21 Feb 2020 | Lorem |
| Citius engages CRO Therapeutics for Phase IIb hemorrhoid study to start in 2019, CEO says | 15 Jan 2019 | Shuan Sim |
| Eidos’ AG10 Phase II too short to identify safety, efficacy a surer bet in amyloid cardiomyopathy; Phase III design should have Pfizer Vyndaqel comparator, experts say | 20 Sep 2018 | Arafa Salam |
| FGF-R valuable target for cholangiocarcinoma but no clear front runner amongst inhibitors under investigation; edge needed in small market, experts say | 17 Jul 2018 | Reynald Castaneda |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer